ReviewInflammopharmacology2026
Visceral leishmaniasis: an integrated review of resistance mechanisms, host immunometabolism, and next generation therapeutics.
Review in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leishmania donovani is the most common cause of visceral leishmaniasis, which has been a significantly neglected tropical disease with high morbidity and mortality rates in the endemic countries. The persistence with a small number of antileishmanial drugs has led to the development and propagation of drug resistance, which undermines treatment efficacy and control initiatives. This review presents a multidisciplinary and in-depth analysis of the mechanisms of drug resistance in VL, integrating parasite-specific determinants with host-level metabolic reprogramming. We discuss the molecular mechanisms of drug neutralisation caused by dysregulation of drug uptake and efflux in aquaglyceroporin-1 (AQP1), as well as additional drug neutralisation caused by thiol-based redox detoxification in the trypanothione pathway. We also discuss the role of the parasite in manipulating host macrophage cholesterol dynamics, lipid raft disruption, and immune suppression to create a permissive intracellular niche that suppresses drug accumulation and drug response. The contribution of sterol remodelling, especially through the parasite-specific LdSMT enzyme and CYP710C1-mediated production of stigmasterol, is addressed in the context of both resistance acquisition and rational drug targeting. On the therapeutic side, the present article assesses the existing evidence base of combination regimens, host-directed approaches, and new oral pipeline of novel oral candidates, under clinical development by DNDi and partner institutions, such as LXE408, DNDI-6174, liposomal nanoformulations. Further, the article provides a survey of the topography of diagnostic instruments, including strong points and translational shortcomings of parasitological confirmation, molecular and serological. Together, this review highlights the necessity of combined, surveillance-based, and target-specific strategies in order to support and prolong the achieved progress in VL eradication.
Indexed as
Identifiers
42734842What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.